Corneal Surgery Device Market by Device Type (Corneal Cross-Linking Systems, Corneal Topographers, Excimer Laser Systems), Procedure (Keratoplasty, Refractive Surgery, Therapeutic Surgery), Technology, Material, End User, Distribution Channel - Global For
Description
The Corneal Surgery Device Market was valued at USD 8.03 billion in 2024 and is projected to grow to USD 8.67 billion in 2025, with a CAGR of 7.77%, reaching USD 14.62 billion by 2032.
A forward-looking introduction that frames clinical convergence, operational pressures, and innovation priorities shaping the modern corneal surgery device environment
The corneal surgery device landscape is undergoing accelerated refinement as clinical techniques, imaging fidelity, and instrumentation converge to elevate patient outcomes and expand therapeutic indications. Surgeons and healthcare providers are increasingly integrating advanced diagnostic mapping with precise surgical platforms, thereby enabling more reproducible procedures and reducing variability in postoperative results. As a result, device developers are pursuing tighter integration between preoperative assessment tools and intraoperative systems to streamline workflows and support decision-making at the point of care.
Moreover, payer scrutiny and value-based care frameworks are reshaping procurement priorities, prompting hospital systems and ambulatory providers to scrutinize total procedural cost, patient throughput, and long-term visual outcomes. Consequently, manufacturers face rising expectations to demonstrate not only clinical efficacy but also operational efficiency and ease of adoption. Taken together, these dynamics are creating a market environment in which innovation must be clinically validated, economically justifiable, and operationally compatible with diverse delivery settings.
How diagnostic precision, procedural standardization, and convergent device ecosystems are redefining therapeutic approaches and competitive dynamics in corneal surgery
Recent years have produced transformative shifts driven by technology miniaturization, algorithmic imaging, and procedural standardization across corneal interventions. High-resolution topography and tomography have transitioned from diagnostic adjuncts to central planning tools, enabling refractive and therapeutic procedures to be tailored at the tissue level. Simultaneously, femtosecond and excimer platforms have advanced in precision and speed, reducing intraoperative variability and shortening recovery windows. These technological advances are changing surgeon expectations and redefining what constitutes a differentiated device.
In parallel, clinical pathways are being rewritten by hybrid approaches that combine cross-linking, laser ablation, and lamellar techniques to treat complex corneal pathologies with eye-preserving intent. Regulatory clarity for incremental innovations has improved in several jurisdictions, encouraging manufacturers to migrate disruptive features from concept to clinical use more rapidly. Consequently, the competitive landscape is realigning around ecosystems that link diagnostics, planning software, and surgical hardware into cohesive solutions that address both clinical efficacy and practice economics.
Strategic sourcing, regional production shifts, and procurement resilience emerging as primary industry responses to new United States tariff changes in 2025
Tariff policy shifts within the United States in 2025 have introduced new considerations for supply chain strategies, sourcing decisions, and commercial pricing for imported ophthalmic devices and components. Manufacturers that rely on globalized production face margin pressure and must re-evaluate cost structures across manufacturing, distribution, and after-sales service. In response, some suppliers are accelerating regional manufacturing investments or negotiating longer-term supply agreements to mitigate the immediate operational impacts of duty changes.
These adjustments are producing downstream effects for hospitals, ambulatory surgical centers, and clinics that must balance procurement budgets with commitments to offering advanced procedures. The need to preserve access to cutting-edge technologies while maintaining predictable procurement costs has heightened interest in local assembly, strategic distributor partnerships, and lifecycle cost analyses that account for tariffs. As a result, commercial strategies are increasingly focused on resilient sourcing models, flexible pricing mechanisms, and customer-facing programs that offset near-term tariff-driven cost volatility.
Segment-level analysis revealing how device categories, procedural subtypes, care settings, and technology choices create distinct adoption and procurement pathways
Segment-level insights reveal nuanced demand drivers and adoption patterns across device categories, procedural types, care settings, technology modalities, material preferences, and distribution pathways. Based on Device Type, market dynamics vary between Corneal Cross-Linking Systems, Corneal Topographers, Excimer Laser Systems, Femtosecond Laser Systems, Keratomes, and Phakic IOL Systems, each exhibiting distinct clinical value propositions and purchasing considerations. Based on Procedure, clinical adoption follows differentiated trajectories across Keratoplasty, Refractive Surgery, and Therapeutic Surgery, with Keratoplasty further delineated into Lamellar Keratoplasty and Penetrating Keratoplasty; the Lamellar Keratoplasty category itself presents clinical sub-specialization in Dalk, Dmek, and Dsaek techniques. The Refractive Surgery corridor is similarly segmented into Lasik, Prk, and Smile approaches, while Therapeutic Surgery encompasses Corneal Cross-Linking and Phototherapeutic Keratectomy, creating multiple pathways for device utility and upgrade cycles.
Based on End User, demand profiles diverge among Ambulatory Surgical Centers, Clinics, and Hospitals, driving variation in procurement processes, capital expenditure timetables, and aftermarket service needs. Based on Technology, the market differentiates between Laser-Based platforms and Manual Instruments, with laser systems typically commanding integration and training investments while manual instruments maintain relevance where cost containment or specific procedural preferences dictate. Based on Material, reusable solutions and single-use disposables present trade-offs between sterilization logistics and per-procedure consistency. Based on Distribution Channel, manufacturers evaluate direct sales relationships against distributor networks to balance market reach with margin control. Collectively, these segmentation lenses highlight where clinical utility, capital intensity, and operational considerations intersect to shape adoption and competitive positioning.
Regional commercial and clinical contours that dictate prioritization of regulatory strategy, product adaptation, and go-to-market models across major global regions
Regional dynamics influence regulatory pathways, reimbursement mechanisms, and clinical practice patterns, and these factors collectively inform how manufacturers prioritize geographic investments and market entry strategies. In the Americas, clinical adoption tends to favor integrated device ecosystems and advanced diagnostic-to-therapy workflows, with private and public payers emphasizing outcomes and procedure efficiency. Europe, Middle East & Africa present a heterogeneous regulatory and reimbursement landscape where tiered access and country-specific procurement frameworks encourage modular commercial models and targeted partnerships. Asia-Pacific demonstrates rapid uptake of new procedural techniques in high-volume centers while also presenting a broad range of resource environments, which favors scalable product architectures and flexible pricing to capture varied segments.
Taken together, these regional contours suggest that product roadmaps and go-to-market strategies should be adapted to local clinical practice norms, regulatory expectations, and purchasing behaviors. Manufacturers that align device feature sets and commercial models with regional priorities will be better positioned to accelerate adoption and sustain service relationships across diverse healthcare ecosystems.
Competitive positioning and partnership strategies that determine long-term adoption and institutional preference in the corneal surgery device market
Competitive dynamics are intensifying as established medtech firms, specialized ophthalmic device manufacturers, and select new entrants pursue differentiated value propositions across the corneal surgery continuum. Incumbent players leverage broad installed bases and service networks to deepen integration between diagnostics and therapeutic platforms, while niche innovators focus on discrete clinical problems such as enhanced topographic mapping or single-procedure disposables that reduce turnaround time. In parallel, partnerships between device makers and software developers are creating opportunities for decision-support tools that improve preoperative planning and intraoperative guidance.
These developments are reshaping procurement rationales: health systems increasingly favor vendors that can demonstrate interoperability, measurable impact on clinical outcomes, and robust post-market support. Meanwhile, capital equipment procurement cycles are influenced by service agreements, training curricula, and upgrade pathways. As a result, companies that combine clinical validation, scalable training programs, and flexible commercial arrangements are consistently better positioned to win long-term institutional relationships and to expand adoption across clinical specialties.
Practical strategic imperatives for manufacturers and providers to advance clinical integration, supply resilience, and demonstrable value propositions in corneal surgery
Actionable recommendations for industry leaders center on three priorities: aligning product design with clinical workflows, stabilizing supply chains against policy-driven disruptions, and demonstrating measurable clinical and economic value to procurement stakeholders. First, invest in seamless integration between diagnostic mapping and surgical execution to reduce variability and shorten learning curves, while also committing to scalable training and proctoring programs that accelerate adoption. Second, diversify manufacturing footprints and develop contingency sourcing strategies to protect margins and delivery timelines in the face of tariff shifts and component scarcity. Third, partner with clinical centers to generate real-world evidence that highlights outcomes, patient satisfaction, and downstream cost implications, thereby underpinning reimbursement conversations and buyer confidence.
Finally, adopt flexible commercial models that address varied end-user needs across ambulatory surgical centers, clinics, and hospitals, and tailor distribution strategies to regional regulatory and procurement nuances. These measures will help mitigate adoption barriers, reinforce clinical credibility, and create defensible differentiation in a market where operational compatibility and demonstrated value are increasingly decisive.
Transparent mixed-method research approach integrating clinical expert input, literature review, and scenario analysis to validate corneal surgery device market insights
The research synthesis underpinning these insights combines qualitative interviews with key opinion leaders, synthesis of peer-reviewed clinical literature, regulatory filings, and structured analysis of device feature sets and service offerings. Primary engagement included conversations with corneal surgeons, procurement leaders at hospitals and ambulatory surgical centers, and device operations managers to capture real-world workflow constraints and adoption drivers. Secondary research involved a systematic review of recent clinical studies, procedure guidelines, and publicly available regulatory summaries to contextualize technological claims and clinical endpoints.
Analytical methods emphasized triangulation across multiple data sources to validate anecdotal observations and to identify convergent trends. Where appropriate, scenario analysis was used to illustrate how commercial and policy variables such as tariff shifts or regional reimbursement changes could influence procurement preferences. Throughout, the methodological approach prioritized transparency in source attribution and a balanced representation of both technological promise and implementation barriers.
Integrated strategic summary emphasizing technological maturation, operational alignment, and evidence-driven commercialization as the foundation for sustainable adoption
In conclusion, the corneal surgery device ecosystem stands at the intersection of technological maturation, evolving clinical practice, and shifting commercial imperatives. Advanced imaging and precision surgical platforms are expanding therapeutic possibilities, while cost containment pressures and policy changes are compelling manufacturers and providers to rethink sourcing, pricing, and value demonstration. Integration between diagnostic and surgical solutions, resilient supply strategies, and robust clinical evidence will be the principal determinants of long-term adoption and differentiation.
For stakeholders across the value chain, the near-term focus should be on aligning product capabilities with real-world workflows, investing in clinician training and support, and forging partnerships that enable rapid evidence generation. By doing so, industry participants can translate technological innovation into sustainable clinical impact and operational success.
Note: PDF & Excel + Online Access - 1 Year
A forward-looking introduction that frames clinical convergence, operational pressures, and innovation priorities shaping the modern corneal surgery device environment
The corneal surgery device landscape is undergoing accelerated refinement as clinical techniques, imaging fidelity, and instrumentation converge to elevate patient outcomes and expand therapeutic indications. Surgeons and healthcare providers are increasingly integrating advanced diagnostic mapping with precise surgical platforms, thereby enabling more reproducible procedures and reducing variability in postoperative results. As a result, device developers are pursuing tighter integration between preoperative assessment tools and intraoperative systems to streamline workflows and support decision-making at the point of care.
Moreover, payer scrutiny and value-based care frameworks are reshaping procurement priorities, prompting hospital systems and ambulatory providers to scrutinize total procedural cost, patient throughput, and long-term visual outcomes. Consequently, manufacturers face rising expectations to demonstrate not only clinical efficacy but also operational efficiency and ease of adoption. Taken together, these dynamics are creating a market environment in which innovation must be clinically validated, economically justifiable, and operationally compatible with diverse delivery settings.
How diagnostic precision, procedural standardization, and convergent device ecosystems are redefining therapeutic approaches and competitive dynamics in corneal surgery
Recent years have produced transformative shifts driven by technology miniaturization, algorithmic imaging, and procedural standardization across corneal interventions. High-resolution topography and tomography have transitioned from diagnostic adjuncts to central planning tools, enabling refractive and therapeutic procedures to be tailored at the tissue level. Simultaneously, femtosecond and excimer platforms have advanced in precision and speed, reducing intraoperative variability and shortening recovery windows. These technological advances are changing surgeon expectations and redefining what constitutes a differentiated device.
In parallel, clinical pathways are being rewritten by hybrid approaches that combine cross-linking, laser ablation, and lamellar techniques to treat complex corneal pathologies with eye-preserving intent. Regulatory clarity for incremental innovations has improved in several jurisdictions, encouraging manufacturers to migrate disruptive features from concept to clinical use more rapidly. Consequently, the competitive landscape is realigning around ecosystems that link diagnostics, planning software, and surgical hardware into cohesive solutions that address both clinical efficacy and practice economics.
Strategic sourcing, regional production shifts, and procurement resilience emerging as primary industry responses to new United States tariff changes in 2025
Tariff policy shifts within the United States in 2025 have introduced new considerations for supply chain strategies, sourcing decisions, and commercial pricing for imported ophthalmic devices and components. Manufacturers that rely on globalized production face margin pressure and must re-evaluate cost structures across manufacturing, distribution, and after-sales service. In response, some suppliers are accelerating regional manufacturing investments or negotiating longer-term supply agreements to mitigate the immediate operational impacts of duty changes.
These adjustments are producing downstream effects for hospitals, ambulatory surgical centers, and clinics that must balance procurement budgets with commitments to offering advanced procedures. The need to preserve access to cutting-edge technologies while maintaining predictable procurement costs has heightened interest in local assembly, strategic distributor partnerships, and lifecycle cost analyses that account for tariffs. As a result, commercial strategies are increasingly focused on resilient sourcing models, flexible pricing mechanisms, and customer-facing programs that offset near-term tariff-driven cost volatility.
Segment-level analysis revealing how device categories, procedural subtypes, care settings, and technology choices create distinct adoption and procurement pathways
Segment-level insights reveal nuanced demand drivers and adoption patterns across device categories, procedural types, care settings, technology modalities, material preferences, and distribution pathways. Based on Device Type, market dynamics vary between Corneal Cross-Linking Systems, Corneal Topographers, Excimer Laser Systems, Femtosecond Laser Systems, Keratomes, and Phakic IOL Systems, each exhibiting distinct clinical value propositions and purchasing considerations. Based on Procedure, clinical adoption follows differentiated trajectories across Keratoplasty, Refractive Surgery, and Therapeutic Surgery, with Keratoplasty further delineated into Lamellar Keratoplasty and Penetrating Keratoplasty; the Lamellar Keratoplasty category itself presents clinical sub-specialization in Dalk, Dmek, and Dsaek techniques. The Refractive Surgery corridor is similarly segmented into Lasik, Prk, and Smile approaches, while Therapeutic Surgery encompasses Corneal Cross-Linking and Phototherapeutic Keratectomy, creating multiple pathways for device utility and upgrade cycles.
Based on End User, demand profiles diverge among Ambulatory Surgical Centers, Clinics, and Hospitals, driving variation in procurement processes, capital expenditure timetables, and aftermarket service needs. Based on Technology, the market differentiates between Laser-Based platforms and Manual Instruments, with laser systems typically commanding integration and training investments while manual instruments maintain relevance where cost containment or specific procedural preferences dictate. Based on Material, reusable solutions and single-use disposables present trade-offs between sterilization logistics and per-procedure consistency. Based on Distribution Channel, manufacturers evaluate direct sales relationships against distributor networks to balance market reach with margin control. Collectively, these segmentation lenses highlight where clinical utility, capital intensity, and operational considerations intersect to shape adoption and competitive positioning.
Regional commercial and clinical contours that dictate prioritization of regulatory strategy, product adaptation, and go-to-market models across major global regions
Regional dynamics influence regulatory pathways, reimbursement mechanisms, and clinical practice patterns, and these factors collectively inform how manufacturers prioritize geographic investments and market entry strategies. In the Americas, clinical adoption tends to favor integrated device ecosystems and advanced diagnostic-to-therapy workflows, with private and public payers emphasizing outcomes and procedure efficiency. Europe, Middle East & Africa present a heterogeneous regulatory and reimbursement landscape where tiered access and country-specific procurement frameworks encourage modular commercial models and targeted partnerships. Asia-Pacific demonstrates rapid uptake of new procedural techniques in high-volume centers while also presenting a broad range of resource environments, which favors scalable product architectures and flexible pricing to capture varied segments.
Taken together, these regional contours suggest that product roadmaps and go-to-market strategies should be adapted to local clinical practice norms, regulatory expectations, and purchasing behaviors. Manufacturers that align device feature sets and commercial models with regional priorities will be better positioned to accelerate adoption and sustain service relationships across diverse healthcare ecosystems.
Competitive positioning and partnership strategies that determine long-term adoption and institutional preference in the corneal surgery device market
Competitive dynamics are intensifying as established medtech firms, specialized ophthalmic device manufacturers, and select new entrants pursue differentiated value propositions across the corneal surgery continuum. Incumbent players leverage broad installed bases and service networks to deepen integration between diagnostics and therapeutic platforms, while niche innovators focus on discrete clinical problems such as enhanced topographic mapping or single-procedure disposables that reduce turnaround time. In parallel, partnerships between device makers and software developers are creating opportunities for decision-support tools that improve preoperative planning and intraoperative guidance.
These developments are reshaping procurement rationales: health systems increasingly favor vendors that can demonstrate interoperability, measurable impact on clinical outcomes, and robust post-market support. Meanwhile, capital equipment procurement cycles are influenced by service agreements, training curricula, and upgrade pathways. As a result, companies that combine clinical validation, scalable training programs, and flexible commercial arrangements are consistently better positioned to win long-term institutional relationships and to expand adoption across clinical specialties.
Practical strategic imperatives for manufacturers and providers to advance clinical integration, supply resilience, and demonstrable value propositions in corneal surgery
Actionable recommendations for industry leaders center on three priorities: aligning product design with clinical workflows, stabilizing supply chains against policy-driven disruptions, and demonstrating measurable clinical and economic value to procurement stakeholders. First, invest in seamless integration between diagnostic mapping and surgical execution to reduce variability and shorten learning curves, while also committing to scalable training and proctoring programs that accelerate adoption. Second, diversify manufacturing footprints and develop contingency sourcing strategies to protect margins and delivery timelines in the face of tariff shifts and component scarcity. Third, partner with clinical centers to generate real-world evidence that highlights outcomes, patient satisfaction, and downstream cost implications, thereby underpinning reimbursement conversations and buyer confidence.
Finally, adopt flexible commercial models that address varied end-user needs across ambulatory surgical centers, clinics, and hospitals, and tailor distribution strategies to regional regulatory and procurement nuances. These measures will help mitigate adoption barriers, reinforce clinical credibility, and create defensible differentiation in a market where operational compatibility and demonstrated value are increasingly decisive.
Transparent mixed-method research approach integrating clinical expert input, literature review, and scenario analysis to validate corneal surgery device market insights
The research synthesis underpinning these insights combines qualitative interviews with key opinion leaders, synthesis of peer-reviewed clinical literature, regulatory filings, and structured analysis of device feature sets and service offerings. Primary engagement included conversations with corneal surgeons, procurement leaders at hospitals and ambulatory surgical centers, and device operations managers to capture real-world workflow constraints and adoption drivers. Secondary research involved a systematic review of recent clinical studies, procedure guidelines, and publicly available regulatory summaries to contextualize technological claims and clinical endpoints.
Analytical methods emphasized triangulation across multiple data sources to validate anecdotal observations and to identify convergent trends. Where appropriate, scenario analysis was used to illustrate how commercial and policy variables such as tariff shifts or regional reimbursement changes could influence procurement preferences. Throughout, the methodological approach prioritized transparency in source attribution and a balanced representation of both technological promise and implementation barriers.
Integrated strategic summary emphasizing technological maturation, operational alignment, and evidence-driven commercialization as the foundation for sustainable adoption
In conclusion, the corneal surgery device ecosystem stands at the intersection of technological maturation, evolving clinical practice, and shifting commercial imperatives. Advanced imaging and precision surgical platforms are expanding therapeutic possibilities, while cost containment pressures and policy changes are compelling manufacturers and providers to rethink sourcing, pricing, and value demonstration. Integration between diagnostic and surgical solutions, resilient supply strategies, and robust clinical evidence will be the principal determinants of long-term adoption and differentiation.
For stakeholders across the value chain, the near-term focus should be on aligning product capabilities with real-world workflows, investing in clinician training and support, and forging partnerships that enable rapid evidence generation. By doing so, industry participants can translate technological innovation into sustainable clinical impact and operational success.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Advances in femtosecond laser technology enhancing micro-incision accuracy and healing outcomes
- 5.2. Integration of real-time intraoperative optical coherence tomography imaging for corneal graft alignment
- 5.3. Development of biocompatible corneal inlays with adjustable refractive properties for presbyopia correction
- 5.4. Growing adoption of artificial intelligence algorithms for personalized corneal surgery planning and outcome prediction
- 5.5. Regulatory shifts accelerating approval of novel collagen cross-linking devices for keratoconus management
- 5.6. Emergence of portable minimally invasive corneal microscopes for outpatient surgery efficiency improvements
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Corneal Surgery Device Market, by Device Type
- 8.1. Corneal Cross-Linking Systems
- 8.2. Corneal Topographers
- 8.3. Excimer Laser Systems
- 8.4. Femtosecond Laser Systems
- 8.5. Keratomes
- 8.6. Phakic IOL Systems
- 9. Corneal Surgery Device Market, by Procedure
- 9.1. Keratoplasty
- 9.1.1. Lamellar Keratoplasty
- 9.1.1.1. Dalk
- 9.1.1.2. Dmek
- 9.1.1.3. Dsaek
- 9.1.2. Penetrating Keratoplasty
- 9.2. Refractive Surgery
- 9.2.1. Lasik
- 9.2.2. Prk
- 9.2.3. Smile
- 9.3. Therapeutic Surgery
- 9.3.1. Corneal Cross-Linking
- 9.3.2. Phototherapeutic Keratectomy
- 10. Corneal Surgery Device Market, by Technology
- 10.1. Laser-Based
- 10.2. Manual Instruments
- 11. Corneal Surgery Device Market, by Material
- 11.1. Reusable
- 11.2. Single-Use
- 12. Corneal Surgery Device Market, by End User
- 12.1. Ambulatory Surgical Centers
- 12.2. Clinics
- 12.3. Hospitals
- 13. Corneal Surgery Device Market, by Distribution Channel
- 13.1. Online
- 13.2. Offline
- 14. Corneal Surgery Device Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Corneal Surgery Device Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Corneal Surgery Device Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Alcon Inc.
- 17.3.2. Bausch & Lomb Incorporated
- 17.3.3. Carl Zeiss Meditec AG
- 17.3.4. Johnson & Johnson Surgical Vision Inc.
- 17.3.5. Nidek Co. Ltd.
- 17.3.6. Ziemer Ophthalmic Systems AG
- 17.3.7. Abbott Medical Optics Inc.
- 17.3.8. Sonomed Escalon
- 17.3.9. Haag-Streit AG
- 17.3.10. Moria Surgical
- 17.3.11. Optos PLC
- 17.3.12. Topcon Corporation
- 17.3.13. Essilor Instruments
- 17.3.14. Oertli Instrumente AG
- 17.3.15. Medtronic PLC
- 17.3.16. Hoya Corporation
- 17.3.17. STAAR Surgical Company
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
